Novo Nordisk Shares Drop After Obesity Drug Price Deal
Novo Nordisk shares fall after Trump deal to cut obesity drug prices, marking a major shift in the U.S. pharmaceutical market. The Danish company, along with rival Eli Lilly, has agreed to lower prices of their leading GLP-1 weight-loss medications. Novo Nordisk and Eli Lilly Agree to Slash Prices According to the announcement, Novo Nordisk…